Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC

Immunotherapy is becoming an accepted treatment modality for many patients with cancer and is now approved for use in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Despite these successes, a minority of patients with HNSCC receiving immunotherapy respond...

Descripción completa

Detalles Bibliográficos
Autores principales: Mann, JE, Hoesli, R, Michmerhuizen, NL, Devenport, SN, Ludwig, ML, Vandenberg, TR, Matovina, C, Jawad, N, Mierzwa, M, Shuman, AG, Spector, ME, Brenner, JC
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332883/
https://www.ncbi.nlm.nih.gov/pubmed/28261333
http://dx.doi.org/10.7150/jca.17547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332883/
https://www.ncbi.nlm.nih.gov/pubmed/28261333
http://dx.doi.org/10.7150/jca.17547

Ejemplares similares